The Demuris proprietary toolbox allows us to rapidly identify leads, and combines our synthetic biology capabilities to optimize these compounds for optimal therapeutic benefit.
£800,000 grant for optimization of novel antibiotics targeting multidrug-resistant tuberculosis. Newcastle, UK – September 11, 2019 – Demuris Limited, a company focused on the discovery and
Focused on the development of novel therapeutics for mitochondrial diseases. Newcastle, UK – 2 August 2019 – The Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle
Demuris has secured a £342,160 grant from Innovate UK to continue the development of a novel class of antibiotics for the treatment of multi-drug resistant